Fennec Pharmaceuticals Files 8-K
Ticker: FENC · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1211583
| Field | Detail |
|---|---|
| Company | Fennec Pharmaceuticals Inc. (FENC) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, sec-filing
TL;DR
FENNEC PHARMACEUTICALS INC. filed an 8-K on Feb 7, 2025. Standard corporate update.
AI Summary
Fennec Pharmaceuticals Inc. filed an 8-K on February 7, 2025, reporting other events and financial statements. The company, previously known as Adherex Technologies Inc., is incorporated in British Columbia, Canada, and operates in the biological products sector.
Why It Matters
This filing indicates Fennec Pharmaceuticals Inc. is providing updates on its corporate activities and financial status to the SEC.
Risk Assessment
Risk Level: low — This is a routine corporate filing with no immediate financial or operational disclosures that suggest elevated risk.
Key Players & Entities
- Fennec Pharmaceuticals Inc. (company) — Registrant
- Adherex Technologies Inc (company) — Former company name
- February 7, 2025 (date) — Date of report
FAQ
What is the primary business of Fennec Pharmaceuticals Inc.?
Fennec Pharmaceuticals Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 7, 2025.
What is the Commission File Number for Fennec Pharmaceuticals Inc.?
The Commission File Number for Fennec Pharmaceuticals Inc. is 001-32295.
Where is Fennec Pharmaceuticals Inc. incorporated?
Fennec Pharmaceuticals Inc. is incorporated in British Columbia, Canada.
What were the previous names of Fennec Pharmaceuticals Inc.?
Fennec Pharmaceuticals Inc. was formerly known as Fennec Pharmaceuticals, Inc. and prior to that, Adherex Technologies Inc.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-02-07 16:52:56
Filing Documents
- fencf-20250207x8k.htm (8-K) — 49KB
- fencf-20250207xex99d1.htm (EX-99.1) — 41KB
- fencf-20250207xex99d1001.jpg (GRAPHIC) — 2KB
- 0001558370-25-000715.txt ( ) — 220KB
- fencf-20250207.xsd (EX-101.SCH) — 3KB
- fencf-20250207_lab.xml (EX-101.LAB) — 16KB
- fencf-20250207_pre.xml (EX-101.PRE) — 10KB
- fencf-20250207x8k_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On February 7, 2025, Fennec Pharmaceuticals Inc. issued a news release announcing that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has commercially launched PEDMARQSI (sodium thiosulfate injection) in Germany. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 99.1 Press Release dated February 7, 2025 Exhibit 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date February 7, 2025 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer